HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.